[1] Guo Z,Li M,Han B,et al.Association of non-alcoholic fatty liver disease with thyroid function:A systematic review and Meta-analysis. Dig Liver Dis,2018,23(1):1-7. [2] 金沛桦,施军平. 非酒精性脂肪性肝病:一种多系统疾病. 实用肝脏病杂志,2017,20(3):257-259. [3] 常成,沈佳,耿昌海. 非酒精性脂肪性肝病中医药治疗进展. 中国中医急症,2013,22(12):2079-2081. [4] Chalasani N,Younossi Z.The diagnosis and management of nonalcoholic fatty liver disease:practice guidance from the american association for the study of liver diseases. Hepatology,2018,67(1):328-357. [5] Eriksson JW,Lundkvist P,Jansson PA,et al.Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes:a double-blind randomised placebo-controlled study. Diabetologia,2018,61(9):1923-1934. [6] Wijarnpreecha K,Panjawatanan P,Lekuthai N,et al.Hyperuricaemia and risk of nonalcoholic fatty liver disease:a Meta-analysis. Liver Int,2017,37(6):906-918. [7] Xu G,Huang K,Zhou J.Hepatic AMP kinase as a potential target for treating nonalcoholic fatty liver disease:evidence from studies of natural products. Curr Med Chem,2018,25(8):889-907. [8] Oikonomou D,Georgiopoulos G,Katsi V,et al.Non-alcoholic fatty liver disease and hypertension:coprevalent or correlated Eur J Gastroenterol Hepatol,2018,30(9):979-985. [9] Xu L,Nagata N.Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance. Adipocyte,2018,56(12):1-8. [10] Abdel-Razik A,Mousa N,Shabana W,et al.Rifaximin in nonalcoholic fatty liver disease:hit multiple targets with a single shot. Eur J Gastroenterol Hepatol,2018,30(10):1237-1246. [11] 陈东风,孙文静,刘凯军,等. 非酒精性脂肪性肝病相关性肝癌的流行病学现状与发病机制. 中华肝脏病杂志,2017,25(2):111-114. [12] Mahli A,Koch A,Fresse K,et al.Iso-alpha acids from hops (Humulus lupulus) inhibit hepatic steatosis,inflammation,and fibrosis. Lab Invest,2018,12(1):1-7. [13] Imai N,Cohen DE.Trimming the fat:acetyl-CoA carboxylase Inhibition for the management of NAFLD. Hepatology,2018,33(6):12-18. [14] 曲颖,陆伦根. 非酒精性脂肪性肝病诊断方面新进展. 中华肝脏病杂志,2016,24(2):85-88. [15] Amanat S,Eftekhari MH,Fararouei M,et al.Genistein supplementation improves insulin resistance and inflammatory state in non-alcoholic fatty liver patients: A randomized, controlled trial. Clin Nutr,2018,37(4):1210-1215. [16] 朱婵艳,周达,范建高. 非酒精性脂肪性肝病的诊断与治疗进展. 中华肝脏病杂志,2016,24(2):81-84. [17] Jung TW,Kang C,Goh J,et al.WISP1 promotes non-alcoholic fatty liver disease and skeletal muscle insulin resistance via TLR4/JNK signaling. J Cell Physiol,2018,233(8):6077-6087. [18] Tsuchida T,Lee YA,Fujiwara N,et al.A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis,fibrosis and liver cancer. J Hepatol,2018,69(2):385-395. [19] Li W,Zhu X,Song Y,et al.Intakes of magnesium, calcium and risk of fatty liver disease and prediabetes. Public Health Nutr,2018,21(11):2088-2095. [20] Li Z,Lin M,Liu C,et al.Fetuin-B links nonalcoholic fatty liver disease to type 2 diabetes via inducing insulin resistance: association and path analyses. Cytokine,2018,108:145-150. [21] Preuss HG,Kaats GR,Mrvichin N,et al.Examining the relationship between nonalcoholic fatty liver disease and the metabolic syndrome in nondiabetic subjects. J Am Coll Nutr,2018,37(6):457-465. [22] Romier B,Ivaldi C,Sartelet H,et al.Production of elastin-derived peptides contributes to the development of nonalcoholic steatohepatitis. Diabetes,2018,67(8):1604-1615. [23] Patel PJ,Hossain F,Horsfall LU,et al.Controlled attenuation parameter in NAFLD identifies risk of suboptimal glycaemic and metabolic control. J Diabetes Complications,2018,32(8):799-804. [24] 赵文霞,张丽慧. 合理应用中成药治疗非酒精性脂肪性肝病. 实用肝脏病杂志,2017,20(2):132-134. [25] 翁思颖,柴可夫,周建扬. 2型糖尿病合并非酒精性脂肪性肝病中医体质分布规律与基因多态性关系研究. 中华中医药杂志,2017,(5):2216-2219. |